Table 2.
Univariate survival analysis of factors associated with progression to cervical SILs.
| Variables | Hazard ratio (95% Wald Robust CL) | P value |
|---|---|---|
| Antiretroviral therapy§ | ||
| HAARTa versus old HAARTb | 0.47 (0.31–0.70) | 0.0002 |
| HAART versus any ARTc | 0.33 (0.18–0.61) | 0.0004 |
| HAART versus no ART | 0.42 (0.30–0.60) | <0.0001 |
| Increased CD4+ cell counts (cells/mm3)§∗ | <0.0001 | |
| By 100 | 0.88 (0.82–0.92) | |
| By 200 | 0.76 (0.68–0.85) | |
| By 300 | 0.66 (0.56–0.78) | |
| By 500 | 0.50 (0.36–0.66) | |
| Increased viral load by 1 log10 § | 1.29 (1.21–1.38) | <0.0001 |
| Duration of HIV infection (for each 10 years of increase)§ | 0.30 (0.22–0.41) | <0.0001 |
| Age (for each 10 years of increase)§ | 0.57 (0.49–0.66) | <0.0001 |
| Menopausal versus premenopausal§ | 0.62 (0.41–0.94) | 0.0225 |
| Race | 0.1891 | |
| White versus black | 0.78 (0.55–1.10) | 0.1580 |
| Hispanic versus non-Hispanic | 0.80 (0.54–1.18) | 0.2526 |
| Number of sexual partners§ | 1.13 (0.85–1.49) | 0.4065 |
| Unprotected heterosexual contact | 1.03 (0.62–1.70) | 0.9246 |
| HIV infection from IV drug use (yes versus no) | 1.46 (1.00–2.13) | 0.0516 |
| Smoking status | 0.0144 | |
| Current smokers versus never smoked | 1.30 (0.94–1.77) | 0.1208 |
| Current smokers versus former smokers | 2.89 (1.32–6.34) | 0.0080 |
HAART: highly active antiretroviral therapy, ART: antiretroviral therapy.
aHAART: current standard HAART regimens (two or more nucleoside reverse transcriptase inhibitors (NRTIs) with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitors (raltegravir) or salvage regimen.
bOld HAART: triple combination antiretroviral regimens containing indinavir, saquinavir, fosamprenavir, nelfinavir, or nevirapine.
cAny ART: not classified as HAART or old HAART.
§Time-dependent covariate.
*The different units are presented for the reader's convenience in the incremental units they may prefer.